A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 with other antitumor therapies in advanced solid tumors to explore the reasonable dosage, safety and efficacy of SHR-A2102 for advanced solid tumors.
Advanced Solid Tumors
DRUG: SHR-A2102|DRUG: Bevacizumab Injection|DRUG: Adebelimab Injection|DRUG: Ametinib Mesylate Tablets|DRUG: Osimertinib Mesylate Tablets
Adverse events (AEs), From day 1 to 90 days after the last dose.|Serious adverse events (SAEs), From day 1 to 90 days after the last dose.|Objective response rate (ORR), About 2 years.
Disease control rate (DCR), About 2 years.|Duration of response (DOR), About 2 years.|Progression free survival (PFS), About 2 years.|Overall survival (OS), About 2 years.
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 with other antitumor therapies in advanced solid tumors to explore the reasonable dosage, safety and efficacy of SHR-A2102 for advanced solid tumors.